NK-92MI细胞
ATCC Number： CRL-2408™
相关**： 其他**
生长状态： 悬浮生长，多细胞聚集
运输方式： 冻存运输
年限： 50 years
数量： 大量
细胞形态： **样
细胞类型： 其他细胞类型
是否是肿瘤细胞： 1
物种来源： 人
Designations: NK-92MI
Depositors: Conkwest Inc.
NK-92MI细胞Biosafety Level: 2
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension, multicell aggregates
Organism: Homo sapiens deposited as human
Morphology: lymphoblast
Source: Disease: malignant non-Hodgkin's lymphoma
Cell Type: natural killer cell; NK cell;
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
DNA Profile (STR): D5S818: 12. 13
D13S317: 9, 12
D7S820: 10, 11
D16S539: 11, 12
vWA: 16, 18
THO1: 6, 9.3
TPOX: 8
CSF1PO: 11, 12
Amelogenin: X, Y
Age: 50 years
Gender: male
Ethnicity: NK-92MI细胞Caucasian
Comments: NK-92 is an interleukin-2 (IL-2) dependent Natural Killer Cell line derived from peripheral blood mononuclear cells from a 50 year old Caucasian male with rapidly progressive non-Hodgkin's lymphoma. NK-92MI is an interleukin-2 (IL-2) independent Natural Killer Cell line derived from the NK-92 (ATCC CRL-2407) cell line by transfection. The parental cells were transfected with human IL-2 cDNA in the retroviral MFG-hIL-2 vector by particle-mediated gene transfer. The transfection is stable, most likely due to integration of the vector into genomic DNA. The cell line is cytotoxic to a wide range of malignant cells; it kills both K562 cells and Daudi cells in chromium release assays. NK-92 and derivative cell line NK-92MI have the following characteristics: surface marker positive for CD2, CD7, CD11a, CD28, CD45, CD54 and CD56 bright; surface marker negative for CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34 and HLA-DR. The parental IL-2 dependent cell line is available as CRL-2407 (NK-92). NK-92MI was shown to contain, express, and synthesize the hIL-2. A culture submitted to the ATCC in September of 1998 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline. The cells were assayed for mycoplasma, by the Hoechst stain, PCR and the standard culture test, after a six-week period following treatment. All tests were negative.
Propagation: ATCC complete growth medium: The base medium for this cell line is Alpha Minimum Essential medium without ribonucleosides and deoxyribonucleosides but with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate . To make the complete growth medium, add the following components to the base medium: 0.2 mM inositol; 0.1 mM 2-mercaptoethanol; 0.02 mM folic acid; horse serum to a final concentration of 12.5%; fetal bovine serum to a final concentration of 12.5%.
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing: Protocol: NK-92MI细胞Cultures can be maintained by centrifuging cells and resuspending cell pellet in fresh medium at 2 - 3 X 105 viable cells/mL. Centrifugation and full replacement of culture medium may be performed for the first subcultures. Cultures can then be maintained by addition of fresh medium. Pipet the cells up and down on the back of the flask every 2-3 days to produce a single cell suspension. Maintain cell density between 2 X 10 5 and 1 X 10 6 viable cells/ml or use a 1:3 spilt ratio.
Preservation: Freeze medium: FBS, 90%; DMSO, 10%
Storage temperature: liquid nitrogen vapor phase
Related Products: recommended serum: ATCC 30-2020
recommended serum: ATCC 30-2040
parental cell line: ATCC CRL-2407 (EBV po
References: 38894: Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260
38969: Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666
40184: Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. NK-92MI细胞PubMed: 10417052
